[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-383051-105":59,"doc-detail-383051-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","anti-her2-drugs-for-the-treatment-of-advanced-her2-positive-breast-cancer","Anti‑HER2 Drugs for the Treatment of Advanced HER2 Positive Breast Cancer","","Anti‑HER2 drugs have transformed outcomes for patients with advanced HER2‑positive breast cancer, a subtype historically linked with poor prognosis due to HER2 overexpression or gene amplification. The review outlines current global metastatic treatment options, including first‑line HER2 pathway blocking monoclonal antibodies, second‑line antibody‑drug conjugates, and further‑line small‑molecule tyrosine kinase inhibitors and targeted agents. It summarizes key clinical‑trial findings, real‑world benefits and adverse risks, and addresses re‑treatment efficacy with trastuzumab, while highlighting emerging questions about optimal sequencing, combinations, endocrine use in luminal HER2 tumors, and special populations such as patients with brain metastases.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/anti-her2-drugs-for-the-treatment-of-advanced-her2-positive-breast-cancer/383051/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/anti-her2-drugs-for-the-treatment-of-advanced-her2-positive-breast-cancer/383051.png","ImageObject",300,407,{"name":92,"@type":93},"Aldword","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-28","2026-09-24",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the rationale for using anti‑HER2 therapies in advanced HER2‑positive breast cancer?","Question",{"text":112,"@type":113},"HER2 overexpression or gene amplification is predictive and prognostic. Targeting the HER2 pathway historically improved outcomes compared with regimens without HER2 blockade.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which anti‑HER2 agents are used across treatment lines for metastatic HER2‑positive breast cancer?",{"text":117,"@type":113},"The text lists worldwide HER2 pathway blocking drugs by line: trastuzumab and pertuzumab (first line), trastuzumab deruxtecan and trastuzumab emtansine (second line), and tucatinib, neratinib, lapatinib, and margetuximab in further lines.",{"name":119,"@type":110,"acceptedAnswer":120},"What key benefits and risks are reported for trastuzumab based on pivotal studies?",{"text":121,"@type":113},"Adding trastuzumab to chemotherapy improved progression‑free survival, duration of response, overall response, and overall survival. The most important adverse event highlighted is cardiac dysfunction, especially with anthracycline plus trastuzumab.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},383051,1790319054,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145},2336478940917,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Current Treatment Options in Oncology (2023) 24:1633–1650 DOI 10.1007/s11864-023-01137-5  \nAnti‑HER2 Drugs for the Treatment of Advanced HER2 Positive Breast Cancer  \nMalwina Stanowicka‑Grada, MDElżbieta Senkus, MD, PhD *  \nAddress  \n* Department of Oncology and Radiotherapy, Medical University of Gdansk, 17 Smoluchowskiego Street, Gdansk 80‑214, Poland  \nEmail: [elsenkus@gumed.edu.pl](elsenkus@gumed.edu.pl)  \n[Published online: 25 October 2023](Published online: 25 October 2023)[ ](Published online: 25 October 2023)© The Author(s) 2023  \nKeywords Metastatic breast cancer (MBC) · HER2 (human epidermal growth factor receptor 2) overexpression · Monoclonal antibodies · Tyrosine kinase inhibitors · Antibody‑drug conjugates  \nOpinion statement  \nApproximately 15–20% of breast cancers (BC) demonstrate HER2 overexpression/gene amplification. Historically, before the era of HER2‑directed therapies, this subtype was associated with poor prognosis. Anti‑HER2 agents dramatically changed the natural course of disease and significantly prolonged patients’ survival. In recent years, a number of new anti‑HER2 therapies have been developed, and their approvals offer new therapeutic options for patients with advanced HER2‑positive breast cancer. At present, HER2 pathway blocking drugs used in the treatment of metastatic breast cancer worldwide include tras‑ tuzumab and pertuzumab in the first‑line treatment; trastuzumab deruxtecan and trastu‑ zumab emtansine in the second line; and tucatinib, neratinib, lapatinib, and margetuximabin further lines of treatment of advanced HER2 positive breast cancer. Additionally, there are many clinical trials underway evaluating drugs blocking the HER2 pathway in advanced disease setting. This article presents new treatment options, discussing the most important findings from clinical trials and real‑world reports, clinical benefits and risks of treatment, as well as efficacy of re‑treatment with trastuzumab in metastatic breast cancer. New data challenge the current standards, and a number of questions arise regarding the optimal sequence of anti‑HER2 targeted therapies, the optimal combination, including endocrine agents in luminal HER2 positive tumors and treatment of special patient population such as patients with brain metastases (BM) .  \nIntroduction  \nBreast cancer is the most common cancer in women and the number one cause of cancer death among women globally [1] .  \nDespite the continuous progress and increasing availability of adjuvant therapies and thus better outcomes in early breast cancer, still 20–30% of patients treated with curative intent will develop distant metastases over the disease course. Additionally, approximately 5–10% of patients present with metastatic disease at the time of the diagnosis [2] .  \nTreatment selection in advanced breast cancer is based on a patient’s and disease characteristics, including, among others, tumor burden, previous treatments,  \nand tumor phenotype, in particular estrogen and progesterone receptor expression and HER2 status [3] . Approximately 15–20% of breast cancers demonstrate HER2 receptor overexpression/gene amplification [4] . Overexpression of HER2 protein or amplification of the gene encoding it is both predictive and prognostic. Historically, until the introduction of drugs blocking the HER2 pathway, the prognosis of patients with HER2-positive advanced breast cancer was dismal. The introduction of anti-HER2 therapies significantly improved the outcomes in this patient subgroup, making them comparable or even superior to those seen in HER2-negative disease [5] .  \nMonoclonal antibodies  \nTrastuzumab  \nTrastuzumab is a humanized monoclonal antibody that binds selectively to HER2 receptor, inhibiting the proliferation of cells that overexpress HER2 . It is also a mediator of antibody-dependent cellular cytotoxicity (ADCC) . The pivotal H0648g phase 3 study, which compared the efficacy of chemotherapy alone to combination of trastuzumab and chemot","cbCaibLW9SzMvdeV","https://ap.wps.com/l/cbCaibLW9SzMvdeV","pdf",387545,18,"English","# Opinion statement\n## Introduction\n## Monoclonal antibodies\n## Trastuzumab","[{\"question\":\"What is the rationale for using anti‑HER2 therapies in advanced HER2‑positive breast cancer?\",\"answer\":\"HER2 overexpression or gene amplification is predictive and prognostic. Targeting the HER2 pathway historically improved outcomes compared with regimens without HER2 blockade.\"},{\"question\":\"Which anti‑HER2 agents are used across treatment lines for metastatic HER2‑positive breast cancer?\",\"answer\":\"The text lists worldwide HER2 pathway blocking drugs by line: trastuzumab and pertuzumab (first line), trastuzumab deruxtecan and trastuzumab emtansine (second line), and tucatinib, neratinib, lapatinib, and margetuximab in further lines.\"},{\"question\":\"What key benefits and risks are reported for trastuzumab based on pivotal studies?\",\"answer\":\"Adding trastuzumab to chemotherapy improved progression‑free survival, duration of response, overall response, and overall survival. The most important adverse event highlighted is cardiac dysfunction, especially with anthracycline plus trastuzumab.\"}]","Anti‑HER2 Drugs for the Treatment of Advanced HER2 Positive Breast Cancer | PDF",1790253909,45]